Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Profit After Tax (2016 - 2026)

Tonix Pharmaceuticals Holding has reported Profit After Tax over the past 4 years, most recently at -$40.2 million for Q1 2026.

  • For Q1 2026, Profit After Tax fell 138.82% year-over-year to -$40.2 million; the TTM value through Mar 2026 reached -$147.2 million, down 9.72%, while the annual FY2025 figure was -$121.6 million, 11.8% up from the prior year.
  • Profit After Tax for Q1 2026 was -$40.2 million at Tonix Pharmaceuticals Holding, up from -$46.9 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$14.9 million in Q1 2024 and troughed at -$78.8 million in Q2 2024.
  • A 4-year average of -$31.8 million and a median of -$28.3 million in 2025 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: tumbled 177.81% in 2024 and later surged 64.11% in 2025.
  • Year by year, Profit After Tax stood at -$27.3 million in 2023, then rose by 16.7% to -$22.8 million in 2024, then crashed by 106.26% to -$46.9 million in 2025, then rose by 14.38% to -$40.2 million in 2026.
  • Business Quant data shows Profit After Tax for TNXP at -$40.2 million in Q1 2026, -$46.9 million in Q4 2025, and -$31.8 million in Q3 2025.